Mechanism of Action and Pharmacodynamics
The drug belongs to gastroprotective agents and is a colloidal compound. Its action unfolds primarily in the acidic environment of the stomach and consists of three interrelated processes:
- Physical protection of mucosal defects. In an acidic environment, the drug causes coagulation (denaturation) of exudate proteins directly on the surface of the ulcer or erosion. As a result, a durable protective film forms, reliably isolating the damaged area from the aggressive action of gastric juice.
- Stimulation of natural barriers. Bismuthate tripotassium dicitrate activates the production of prostaglandin $E_2$, leading to enhanced synthesis of protective gastric mucus.
- Antibacterial action. Unlike many other gastroprotectants, this drug exhibits pronounced anti-Helicobacter activity. It directly inhibits the growth and replication of Helicobacter pylori. This effect is mediated by the general properties of inorganic astringents—the ability to coagulate microbial cell proteins, thereby disrupting cellular viability.
Classification and Difference from Antacids
In fundamental pharmacology, bismuth salts are classified as inorganic astringents (weak solutions of heavy metal salts). This broad group also includes bismuth subnitrate, dermatol (bismuth subgallate), and xeroform (bismuth tribromophenate).
It is important to clearly differentiate bismuth-based gastroprotectants from true antacids. Antacids (e.g., magnesium oxide, algeldrate, sodium bicarbonate) act by directly neutralizing hydrochloric acid chemically within the gastric lumen. Their onset is rapid, but the duration is short (30–60 minutes), and they are used for the symptomatic relief of pain and heartburn.
Bismuth tripotassium dicitrate does not lower acidity directly. On the contrary, an acidic environment is required to activate its protective properties (protein coagulation). Unlike adsorbing antacids (such as bismuth subnitrate, which is effective regardless of acidity), the colloidal preparation works specifically as a structural protector.
Indications for Use
The primary clinical niche for the drug is gastroenterology. It is administered enterally (orally) for:
- Peptic ulcer disease of the stomach and duodenum.
- Chronic gastritis (especially hyperacid gastritis) and duodenitis.
- Gastrointestinal disorders associated with H. pylori infection.
Courses of treatment with combination bismuth regimens for peptic ulcer disease are typically prolonged, lasting from 1 to 3 months. Administration is recommended after meals.
Adverse Effects and Precautions
When prescribing bismuth tripotassium dicitrate, clinicians must warn patients about a specific adverse effect: dark green or black discoloration of the stool. This is a normal chemical reaction within the intestinal lumen; however, clinically it mimics melena. Physicians must carefully differentiate this effect from actual gastrointestinal bleeding.
- Additionally, like other bismuth preparations, the agent may cause oral mucosal lesions presenting as gingivitis and stomatitis.
Historical note: Previously, bismuth preparations (along with arsenic) were administered intramuscularly to treat syphilis because they blocked sulfhydryl (-SH) groups of Treponema pallidum enzymes. Today, they are virtually unused in venereology, having been superseded by antibiotics.
Dosage Forms and Prescription Guidelines
According to reference formularies, the drug is used in tablet form.
- Dosage form: 0.12 g tablets.
- Route of administration: Oral, 0.12 g 3–4 times daily.